A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 172
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : AA
Long Form : abiraterone acetate
No. Year Title Co-occurring Abbreviation
2020 A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. AR, BMBs, CYP17, IHC, mCRPC
2020 A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. mCRPC, TTF
2020 A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer. mCRPC, OS, PFS
2020 Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients. ---
2020 Abiraterone acetate treatment lowers 11-oxygenated androgens. AAP, CRPC, CYP17A1
2020 Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: A microsimulation model. ADT, DC, ICER, mCSPC, OS, QALYs
2020 Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial. AEM, mCRPC
2020 Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. ctDNA, ENZA, OS, TTP
2020 Clinical outcomes of abiraterone acetate and predictors of its treatment duration in metastatic castration-resistant prostate cancer: Real-world experience in the Southeast Asian cohort. bPFS, HR, mCRPC, OS
10  2020 Corticosteroids alleviate adverse events associated with enzalutamide in patients with metastatic castration-resistant prostate cancer. AEs, ARAT, ENZ, mCRPC
11  2020 Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective. ADT, AEs, CEA, GDPpc, ICER, mCSPC, QALYs, RCTs, WTP
12  2020 Early PSA response to antiandrogen therapy in metastatic castration-resistant prostate carcinoma patients: A predictive marker for progression-free survival? mCRPC, PFS, PSA, RR
13  2020 Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223. 223Ra, mCRPC
14  2020 Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities. CI, CVD, CVDs, ENZ, RR
15  2020 Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study. mCRPC, NLR, PSA
16  2020 Pharmacotherapeutic strategies for castrate-resistant prostate cancer. CRPC, ENZ
17  2020 Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. mCRPC, OS, PFS, PSA
18  2020 PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate. mCRPC, NLR, OS, PSA
19  2020 Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone. ---
20  2020 Treatment gains from the "sandwich method" of abiraterone acetate for men with metastatic prostate cancer: a case report and sharing of our experience. PCa, RP
21  2019 A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer. AAP, AEs, HRQoL, mPCa
22  2019 A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. CTC, PI3K, PSA
23  2019 A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy setting. mCRPC
24  2019 Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study. ADT, HR, mCSPC
25  2019 An LC-MS/MS method for quantification of abiraterone, its active metabolites D(4)-abiraterone (D4A) and 5alpha-abiraterone, and their inactive glucuronide derivatives. ABI, AR, CYP17A1, D4A
26  2019 Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis. AEs, mCRPC, OS, PFS
27  2019 Inhibition of autophagy significantly increases the antitumor effect of Abiraterone in prostate cancer. PCa
28  2019 Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer. DP, NED, rPFS
29  2019 Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. AR, CPRC, CTC
30  2019 Predictive factors for abiraterone withdrawal syndrome. AWS, mCRPC
31  2019 Prognostic factors for patients treated with abiraterone. mCRPC, PSAr
32  2019 Qualitative study of patients with metastatic prostate cancer to adherence of hormone therapy. ENZ, mCRPC
33  2019 Radium 223 combined with new hormone therapies for the treatment of castrate-resistant metastatic prostate cancer: scientific evidence and sharing of our experience. CRPC, PRAC
34  2019 Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer. CI, HR, mCRPC, PFS, PSA
35  2019 [CLINICAL OUTCOMES OF ABIRATERONE ACETATE FOR TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER: A RETROSPECTIVE ANALYSIS]. CRPC, ENZ, PSA
36  2018 Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes. ADT, AEs, BMI, CVEs, ECOG, OS, PDN, PFS, PS, PSA
37  2018 Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors. ADT, mCRPC, OS, PSA, rPFS
38  2018 Abiraterone Acetate for Cushing Syndrome: Study in a Canine Primary Adrenocortical Cell Culture Model. CS
39  2018 Abiraterone acetate in the treatment of prostate cancer. ---
40  2018 Abiraterone acetate withdrawal syndrome: Speculations on the underlying mechanisms. CAB, PSA
41  2018 Abiraterone acetate, enzalutamide and their sequence for castration-resistant prostate cancer : Adherence, survival and hospitalization analysis of amedical claims database. CRPC, ENZ, MPR, OS
42  2018 Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy. ADT, HRs, HSPC, mHSPC, OS, PFS
43  2018 Abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 'real-life' studies. mCRPC, OS, PFS, PRISMA, PSA
44  2018 Abiraterone in metastatic castration-resistant prostate cancer: Efficacy and safety in unselected patients. mCRPC
45  2018 Baseline neutrophil-to-lymphocyte ratio predicts the prognosis of castration-resistant prostate cancer treated with abiraterone acetate. CI, CRPC, NLR, OS, PSA
46  2018 Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer. CRPC, DTX, OS, PFS, PSA
47  2018 Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation. CAD, pts
48  2018 Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients. ---
49  2018 Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy+ Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer. ADT, mCRPC, mHSPC
50  2018 Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan. ARATA, DTX, ENZ, mCRPC, OS, PFS, PSA
51  2018 Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naive metastatic castration-resistant prostate cancer patients with or without the ineligible clinical factors of the COU-AA-302 study. mCRPC, OS, PFS
52  2018 Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade. CAB, CRPC, OS, PFS, PSA
53  2018 Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer. CRPC, CSPC
54  2018 HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. ---
55  2018 Kinetics of prostate-specific antigen (PSA) as a marker of abiraterone acetate (AA) efficacy in patients (p) with metastatic castrate-resistant prostate cancer (mCRPC). mCRPC, PSA
56  2018 Long-term abiraterone withdrawal syndrome. AWS, PSA
57  2018 No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer. ARAT, ENZ, mCRPC, OS, PFS, PS, PSA
58  2018 Outcome of Patients with Metastatic Castration-resistant Prostate Cancer After PSA Progression with Abiraterone Acetate. CI, mCRPC, PSA
59  2018 Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer. AE, AR, CRPC, CYP17, DLT, DT
60  2018 Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. CRPC, LOW, PFS, PSA, STD
61  2018 Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis. ADT, DOC, HR, mHSPC, NMAs, OS, QOL, RCTs, rPFS
62  2018 Testosterone metabolites inhibit proliferation of castration- and therapy-resistant prostate cancer. CRPC, DHT, ERalpha, ERbeta, hiPLNCaP
63  2017 Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes. DX, mCRPC
64  2017 Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal. AAP, AC, BSC, CS, ERG, ICERs, ITT, KSR, mCRPC, NICE, PAS
65  2017 Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction. mCRPC, PROs, PSA
66  2017 Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization : Analysis of amedical claims database. CRPC, MPR, OS
67  2017 Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison. OS
68  2017 Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts. AR, nGR, PDXs
69  2017 Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer. CgA, mCRPC, NSE, OS, PSA-PFS, rPFS
70  2017 Comparative Assessment of Clinical Outcomes Between Abiraterone Acetate and Enzalutamide in Patients With Docetaxel-Naive Metastatic Castration-Resistant Prostate Cancer: Experience in Real-World Clinical Practice in Japan. ENZ, mCRPC, PS, PSA
71  2017 Comparative Assessment of Efficacies Between 2Alternative Therapeutic Sequences With NovelAndrogen Receptor-Axis-Targeted Agentsin Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer. ARAT, ENZ, mCRPC, OS, PFS, PSA
72  2017 Development and validation of a novel LC-MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: Innovation in separation of diastereoisomers without use of a chiral column. ---
73  2017 Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate. ADT, bPFS, mCRPC, PFS, TTCRPC
74  2017 Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide. ENZ, HR, IPTWs, mCRPC
75  2017 Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel. ADT, CAB, CRPC
76  2017 Enzalutamide (E) vs abiraterone acetate (AA) in the treatment of metastatic, castration-resistant prostate cancer. Indirect comparisons and network meta-analysis for clinical practice. ---
77  2017 First Line Androgen Deprivation Therapy Duration Is Associated with the Efficacy of Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer after Docetaxel. ADT, AEs, CRPC
78  2017 High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. mCRPC, PSA
79  2017 Impact of Abiraterone Acetate and Enzalutamide on Symptom Burden of Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer. CN, ESAS, EZ, mCRPC, MMRM
80  2017 Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide. ARAT, ENZ, mCRPC, OS, PFS, PS, PSA
81  2017 Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naive, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide. ENZ, mCRPC, PFS, PSA
82  2017 Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review. ENZ, mCRPC, PSA
83  2017 Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer. CgA, mCRPC, NED, NSE, ULN
84  2017 Intracrine androgen biosynthesis in renal cell carcinoma. AR, CRPC, RCC
85  2017 Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis. RR
86  2017 Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. AR, CRPC, DLTs, ECOG PS, MTD, mTOR, PCWG2, PI3K, PK, PSA, PTEN, RDE
87  2017 Prognostic Value of Automated Bone Scan Index in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate. BSI, CRPC, ENZ, ENZ/AA, OS
88  2017 Prostate-Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer. mCRPC, PFS, PSA
89  2017 Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer. mCRPC, PSA
90  2017 Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study. ---
91  2017 The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. DFCI, JHU, TTP
92  2017 Treatment sequence in castration-resistant prostate cancer: A retrospective study in the new anti-androgen era. CRPC, DOC, EZL, PSA
93  2017 Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence. CEA, EBRT, mCRPC, mPC, PC, QHES, ZA
94  2017 Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel? HR, mCRPC, OS, ROC
95  2016 A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). AR, BC, CBR, CI, CR, ORR, PFS, PR, SD, triple-negative
96  2016 A single-center experience with abiraterone as treatment for metastatic castration-resistant prostate cancer. AR, CRPC, mCRPC, PSA
97  2016 Abiraterone acetate after progression with enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis. mCRPC, OS, PFS, PSA
98  2016 Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience. mCRPC, OS, PFS, PSA
99  2016 Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program. mCRPC, PSA
100  2016 Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. ACC, PgR